Israel’s aMoon fund, has invested $5 million in the new NanoGhost anti-cancer therapy of Technion Professor Marcelle Machluf. (reported here previously). In lab tests NanoGhost reduced small lung carcinoma, prostate, and pancreatic cancer tumors, by as much as 85%.
https://www.timesofisrael.com/ghost-cell-startup-that-targets-deadliest-cancers-gets-funding-boost